Ruiji Biotechnology
1
1
- Areas of investment
Summary
Among the various public portfolio startups of the fund, we may underline Ringpai National Chain Veterinary Hospital, Ringpai National Chain Veterinary Hospital Moreover, a startup needs to be at the age of 6-10 years to get the investment from the fund. Among the most popular fund investment industries, there are Clinical Trials, Health Care.
The high activity for fund was in 2018. The fund is constantly included in less than 2 investment rounds annually.
The usual cause for the fund is to invest in rounds with 3 partakers. Despite the Ruiji Biotechnology, startups are often financed by Huatai New Industry Fund, Goldman Sachs. The meaningful sponsors for the fund in investment in the same round are Huatai New Industry Fund, Goldman Sachs. In the next rounds fund is usually obtained by Guangzhou YUEXIU Industrial Investment Fund, Huatai New Industry Fund, Goldman Sachs.
Investments analytics
Analytics
- Total investments
- 1
- Lead investments
- 0
- Investments by industry
- Health Care (1)
- Hospital (1)
- Clinical Trials (1)
- Investments by region
-
- China (1)
- Peak activity year
- 2018
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 9
- Group Appearance index
- 1.00
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.